Zobrazeno 1 - 10
of 326
pro vyhledávání: '"Janis M. Taube"'
Autor:
Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional r
Externí odkaz:
https://doaj.org/article/44edc95deb6444eabbd3e50a4991237d
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
Autor:
Nirmish Singla, Thomas R. Nirschl, Aleksandar Z. Obradovic, Eugene Shenderov, Kara Lombardo, Xiaopu Liu, Alice Pons, Jelani C. Zarif, Steven P. Rowe, Bruce J. Trock, Hans J. Hammers, Trinity J. Bivalacqua, Phillip M. Pierorazio, Julie S. Deutsch, Tamara L. Lotan, Janis M. Taube, Yasser M. A. Ged, Michael A. Gorin, Mohamad E. Allaf, Charles G. Drake
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract Novel perioperative strategies are needed to reduce recurrence rates in patients undergoing nephrectomy for high-risk, non-metastatic clear cell renal cell carcinoma (ccRCC). We conducted a prospective, phase I trial of neoadjuvant nivolumab
Externí odkaz:
https://doaj.org/article/98ed340a1cfb40a2a956efc49983a1b8
Autor:
Paolo A. Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Luigi Buonaguro, Sandra Demaria, Leisha A. Emens, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Christopher A. Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M. Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M. Taube, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Over the past decade, immunotherapy has become an increasingly fundamental modality in the treatment of cancer. The positive impact of immune checkpoint inhibition, especially anti-programmed death (PD)-1/PD-ligand (L)1 blockade, in patients
Externí odkaz:
https://doaj.org/article/c7c0a3307fce4f8da5d3d700a08bd2c5
Autor:
Margaret Eminizer, Melinda Nagy, Elizabeth L. Engle, Sigfredo Soto-Diaz, Andrew Jorquera, Jeffrey S. Roskes, Benjamin F. Green, Richard Wilton, Janis M. Taube, Alexander S. Szalay
Publikováno v:
Cancers, Vol 15, Iss 12, p 3109 (2023)
Multispectral, multiplex immunofluorescence (mIF) microscopy has been used to great effect in research to identify cellular co-expression profiles and spatial relationships within tissue, providing a myriad of diagnostic advantages. As these technolo
Externí odkaz:
https://doaj.org/article/c9aa4870f7c744acad9ba7918bed27cb
Autor:
Paolo A. Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A. Emens, Robert Ferris, Silvia C. Formenti, Jerome Galon, Samir N. Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Janis M. Taube, John Timmerman, Bernard A. Fox, Patrick Hwu, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-16 (2021)
Abstract Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-
Externí odkaz:
https://doaj.org/article/07442960a2f94c70a8eca356003aaba9
Autor:
Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke, Iman Osman, Michael A. Postow, Ryan J. Sullivan, Janis M. Taube, Giorgio Trinchieri, Hassane M. Zarour, Corrado Caracò, Magdalena Thurin
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-22 (2020)
Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly impr
Externí odkaz:
https://doaj.org/article/f2b099b821ea4c5eaa13a1fff3485d97
Autor:
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with
Externí odkaz:
https://doaj.org/article/1bbf8602f6f8428183fdc7d49f984cca
Autor:
Sneha Berry, Nicolas Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie Stein, Elizabeth Engle, Drew Pardoll, Robert Anders, Tricia Cottrell, Janis M. Taube, Ben Tran, Mark Voskoboynik, James Kuo, Yung-Lue Bang, Hyun-Cheo Chung, Myung-Ju Ahn, Sang-We Kim, Ayesh Perera, Daniel Freeman, Ikbel Achour, Raffaella Faggioni, Feng Xiao, Charles Ferte, Charlotte Lemech, Funda Meric-Bernstam, Theresa Werner, Stephen Hodi, Wells Messersmith, Nancy Lewis, Craig Talluto, Mirek Dostalek, Aiyang Tao, Sarah McWhirter, Damian Trujillo, Jason Luke, Chunxiao Xu, BoMarelli, Jin Qi, Guozhong Qin, Huakui Yu, Molly Jenkins, Kin-Ming Lo, Joern-Peter Halle, Yan Lan, Matthew Taylor, Nicholas Vogelzang, Allen Cohn, Daniel Stepan, Robert Shumaker, Corina Dutcus, Matthew Guo, Emmett Schmidt, Drew Rasco, Marcia Brose, Christopher Di Simone, Sharad Jain, Donald Richards, Carlos Encarnacion, James Mier, Jeongshin An, Yeun-yeoul Yang, Won-Hee Lee, Jinho Yang, Jong-kyu Kim, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Joohyun Woo, Jong Bin Kim, Hyungju Kwon, Woosung Lim, Nam Sun Paik, Yoon-Keun Kim, Byung-In Moon, Filip Janku, David Tan, Juan Martin-Liberal, Shunji Takahashi, Ravit Geva, Ayca Gucalp, Xueying Chen, Kulandayan Subramanian, Jennifer Mataraza, Jennifer Wheler, Philippe Bedard
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included in this correction.
Externí odkaz:
https://doaj.org/article/5e0fdcdf298e4148a8ad792b96d6446a
Autor:
Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul T. Nghiem, Suzanne L. Topalian, Janis M. Taube
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Abstract Background We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. Methods Pretreatment FFPE tumo
Externí odkaz:
https://doaj.org/article/76e43af2693646548cca3682365754c1
Autor:
David L. Rimm, Gang Han, Janis M. Taube, Eunhee S. Yi, Julia A. Bridge, Douglas B. Flieder, Robert Homer, Anja C. Roden, Fred R. Hirsch, Ignacio I. Wistuba, Lajos Pusztai
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-3 (2019)
Abstract The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the
Externí odkaz:
https://doaj.org/article/36bf31ee90614449952120245cb37456